Market capitalization | $71.43m |
Enterprise Value | $72.94m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.31 |
P/S ratio (TTM) P/S ratio | 1.28 |
P/B ratio (TTM) P/B ratio | 5.51 |
Revenue growth (TTM) Revenue growth | 8.00% |
Revenue (TTM) Revenue | $55.75m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Exagen Inc forecast:
6 Analysts have issued a Exagen Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 56 56 |
8%
8%
|
|
Gross Profit | 33 33 |
18%
18%
|
|
EBITDA | -14 -14 |
44%
44%
|
EBIT (Operating Income) EBIT | -15 -15 |
42%
42%
|
Net Profit | -17 -17 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
Head office | United States |
CEO | John Aballi |
Employees | 179 |
Founded | 2002 |
Website | www.exagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.